Gates Oil Filler Cap for 2016 Volvo 2.5L S60 En Cross Complete Free Shipping Country L5 Gates Oil Filler Cap for 2016 Volvo 2.5L S60 En Cross Complete Free Shipping Country L5 $5 Gates Oil Filler Cap for 2016 Volvo S60 Cross Country 2.5L L5 En eBay Motors Parts & Accessories Car & Truck Parts & Accessories 2.5L,L5,2016,Cap,Volvo,Oil,Cross,Filler,mellorparishcentre.org,/Lutra1855987.html,Country,En,for,Gates,S60,$5,eBay Motors , Parts & Accessories , Car & Truck Parts & Accessories 2.5L,L5,2016,Cap,Volvo,Oil,Cross,Filler,mellorparishcentre.org,/Lutra1855987.html,Country,En,for,Gates,S60,$5,eBay Motors , Parts & Accessories , Car & Truck Parts & Accessories $5 Gates Oil Filler Cap for 2016 Volvo S60 Cross Country 2.5L L5 En eBay Motors Parts & Accessories Car & Truck Parts & Accessories

Gates Oil Filler Cap for 2016 Volvo 2.5L Genuine S60 En Cross Complete Free Shipping Country L5

Gates Oil Filler Cap for 2016 Volvo S60 Cross Country 2.5L L5 En

$5

Gates Oil Filler Cap for 2016 Volvo S60 Cross Country 2.5L L5 En

|||

Item specifics

Condition:
New
Brand:
Gates
Type:
Engine Oil Filler Cap
Item Length:
3.630
Manufacturer Part Number:
SX-1818 2016 Engine Cylinder Block
Interchange Part Number:
Dayco CARQUEST C343 Ford ACDelco GM 44-29
Compatible Make:
Volvo
Compatible Model:
S60 Cross Country
Compatible Year:
2016
Core Charge:
Free - No Core Charge
Fitment Type:
Direct Replacement
Bundle Description:
1 pc Genuine Gates Engine Oil Filler Cap
UPC:
Does not apply




Gates Oil Filler Cap for 2016 Volvo S60 Cross Country 2.5L L5 En

CURRENT ISSUE
May, 2022

No. 107 (5)

2020 Impact Factor: 9.941 Submission > Acceptance: 80 days
ARTICLES IN THREE SENTENCES
Article

Germline GATA2 variant disrupting endothelial eNOS function and angiogenesis can be restored by c-Jun/AP-1 upregulation

Germline GATA2 gene variants have been associated with several inherited and acquired hematologic disorders, and thrombosis has been reported in 25% of patients. Authors demonstrated that GATA2 deficiency is associated with defective expression of eNOS by platelets and endothelial cells with impaired NO production, suggesting that this may represent an important thrombogenic mechanism. They also identified a therapeutic option, through atorvastatin, able to restore eNOS expression and angiogenesis in GATA2 deficiency in vitro.

Giulio Purgatorio et al.

Letter

SF3B1-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity

This study includes all consecutive WHO-defined MDS/MPN patients of Mayo Clinic from 1994 to 2020.Next-generation sequencing information at diagnosis was available for 444 (57%) patients. Authors combined all SF3B1-mutant MDS/MPN patients into one category (n=78) and compared them to their wild-type counterparts (n=446). Leukemia-free survival and overall survival in MDS/MPN patients with SF3B1 mutations were significantly better compared to SF31B wild-type MDS/MPN patients.

Abhishek A. Mangaonkar et al.

Article

Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients – a matched control multicenter cohort study

Data regarding efficacy and toxicity of CAR-T cell therapy in the elderly, geriatric population are insufficient. This study explored the characteristics and outcome of 47 consecutive patients, 70 years or older, referred for CAR-T. The outcomes of CAR-T cell therapy are comparable between elderly, geriatric and younger patients, indicating that age as per se should not preclude CAR-T cell administration.

Ron Ram et al.

Article

Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma

In this prospective pilot study, authors evaluated a rituximab/prednisone prephase treatment strategy in 33 older, vulnerable patients with newly diagnosed DLBCL. This prephase therapy was feasible with acceptable toxicity profiles and excellent long-term survival. Prephase therapy with rituximab/prednisone should be considered for all older, vulnerable DLBCL patients prior to curative intent, anthracycline-based chemoimmunotherapy.

Richard J. Lin et al.

TAKE ADVANTAGE FROM HAEMATOLOGICA